Home / Business and Economy / UPS Invests $48M in Cold Chain for Pharma
UPS Invests $48M in Cold Chain for Pharma
2 Jul
Summary
- UPS invested $48 million in 27 temperature-controlled cross-dock facilities.
- The investment aims to secure more business from healthcare shippers.
- Facilities are strategically located near airports for swift transport transitions.
UPS recently committed $48 million to bolster its network of temperature-controlled cross-dock facilities. This initiative involves the establishment of 27 new or enhanced locations in key U.S. and international markets, signaling a significant push to expand its healthcare logistics services.
These advanced facilities are primarily located at or near airports. This proximity facilitates rapid, temperature-controlled transitions for sensitive shipments between air and ground transportation. This capability is vital for maintaining the integrity of products such as biologics and GLP-1 injectables, ensuring they remain within required temperature ranges.
The investment is a strategic effort by UPS to capture a larger share of the lucrative healthcare shipping market. The company's healthcare division has shown strong performance, generating over $11 billion in revenue last year. This focus aligns with UPS's broader strategy to cultivate high-margin business segments beyond traditional e-commerce.
Rival FedEx is also intensifying its pursuit of healthcare business, having recently formed a dedicated Life Sciences organization. This competitive landscape highlights the growing importance of specialized logistics for the pharmaceutical and biotech industries.
